
Release date: 2026-09-30 09:31:49 Article From: Lucius Laos Recommended: 48
Adjunctive therapy for focal-onset seizures (with or without secondary generalization) in adults inadequately controlled by ≥2 antiseizure medications.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:9932025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:11542024-09-07
Pancreatic cancer, known as the “king of cancers,” has long been one of the hardest barriers to brea···【more】
Recommended:1212026-13-11
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended:9342026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:5812026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:8132026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:8042026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:6372026-03-08

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram: Vira
No.:0085253923643

zalo
Telegram name: Vira
No.:0085253923643